Search Result

Results for "

Morphine

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adenosine Receptor (1) Amyloid-β (2) Apoptosis (4) Bacterial (2) Biochemical Assay Reagents (2) Calcium Channel (6) CaMK (1) Cholecystokinin Receptor (3) Cholinesterase (ChE) (2) CRFR (1) CXCR (1) Cyclic GMP-AMP Synthase (3) Cytochrome P450 (1) DNA/RNA Synthesis (1) Dopamine Receptor (2) Drug Metabolite (2) Endogenous Metabolite (3) Environmental Pollutants (1) Epigenetic Reader Domain (3) ERK (3) Flavivirus (1) Histamine Receptor (1) HIV (2) HIV Integrase (1) iGluR (1) Integrin (1) Isotope-Labeled Compounds (2) Melanocortin Receptor (1) Na+/K+ ATPase (1) nAChR (2) Neuropeptide FF Receptor (1) NF-κB (1) NO Synthase (1) Opioid Receptor (25) Orexin Receptor (OX Receptor) (3) Parasite (1) Phosphodiesterase (PDE) (2) PKA (7) PKC (2) Potassium Channel (1) Pyruvate Kinase (1) Reference Standards (5) Sigma Receptor (1) Thyroid Hormone Receptor (1) Tyrosinase (1) Tyrosine Hydroxylase (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (9) Endocrinology (3) Infection (4) Inflammation/Immunology (3) Metabolic Disease (5) Neurological Disease (60)
Oligonucleotides:	Guanosine (1) Nucleoside Analogs (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16900

Rolipram Maximum Cited Publications 19 Publications Verification (R,S)-Rolipram; (±)-Rolipram; ZK 62711	Bacterial HIV Phosphodiesterase (PDE) Epigenetic Reader Domain Amyloid-β	Infection Neurological Disease Cancer
Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

HY-P0288

[Leu5]-Enkephalin 2 Publications Verification Leu-enkephalin; Leucine enkephalin; Leucyl-enkephalin	Opioid Receptor Endogenous Metabolite	Neurological Disease
[Leu5]-Enkephalin is a pentapeptide with morphine like properties. [Leu5]-Enkephalin is a five amino acid endogenous peptide that acts as an agonist at opioid receptors.

HY-10895

SB-334867 5+ Cited Publications SB 334867A	Orexin Receptor (OX Receptor)	Neurological Disease Endocrinology
SB-334867 (SB 334867A) is an excellent,selective and blood-brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pK_b=7.4), 100-fold over 5-HT_2B, 5-HT_2C with pK_i values of 5.4 and 5.3, respectively . SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo .

HY-P1291

PKI 14-22 amide,myristoylated 3 Publications Verification	PKA Epigenetic Reader Domain Flavivirus	Infection Neurological Disease
PKI 14-22 amide, myristoylated is a selective, cAMP-dependent, competitive PKA inhibitor with K_i=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated can prevent the development of morphine analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated can be used in research fields such as opioid tolerance mechanisms and antiviral drugs .

HY-P2798

Cholinesterase, Horse serum EC 3.1.1.8; BCHE, Horse serum	Cholinesterase (ChE)	Neurological Disease
Cholinesterase, Horse serum infers to acetylcholinesterase (AChE) and butyryl cholinesterase (BChE). AChE and BChE catalyze the hydrolysis of 6-MAM to morphine .

HY-N0541

Pseudoginsenoside F11 2 Publications Verification Ginsenoside A1	Endogenous Metabolite	Others
Pseudoginsenoside F11 (Ginsenoside A1), a component of Panax quinquefolium (American ginseng), has been demonstrated to antagonize the learning and memory deficits induced by scopolamine, morphine and methamphetamine in mice.

HY-B0424

Nitrendipine 3 Publications Verification BAY-E-5009	Calcium Channel Apoptosis	Cardiovascular Disease Neurological Disease Cancer
Nitrendipine (BAY-E-5009) is an orally active analog of Nifedipine (HY-B0284) and dihydropyridine calcium channel blocker. Nitrendipine induces Apoptosis. Nitrendipine has antihypertensive effects. Nitrendipine blocks alcohol and Morphine withdrawal symptoms. Nitrendipine reduces right ventricular hypertrophy and pulmonary vascular changes induced by intermittent hypoxia. Nitrendipine has anticancer effects on neuroblastoma .

HY-10895A

SB-334867 free base 5+ Cited Publications SB334867A free base	Orexin Receptor (OX Receptor)	Neurological Disease Endocrinology
SB-334867 free base (SB334867A free base) is an excellent, selective and blood–brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pK_b=7.4), 100-fold over 5-HT_2B, 5-HT_2C with pK_i values of 5.4 and 5.3, respectively . SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo .

HY-P1248

Neuropeptide FF NPFF	Neuropeptide FF Receptor	Cardiovascular Disease Neurological Disease
Neuropeptide FF (NPFF), an octapeptide belonging to the RF-amide family of peptides, is a NPFF1 and NPFF2 receptors agonist with K_i values of 2.82 nM and 0.21 nM, respectively. Neuropeptide FF induces abstinence syndrome, exerts antiopioid and analgesic effects, releases via calcium-dependent mechanisms from rat spinal cord, regulates memory, autonomic function, and neuroendocrine function, modulates pain and opioid antinociception, reduces food intake, stimulates water intake, alters cardiovascular parameters, and shows differential activity in hypothalamic paraventricular nucleus neurons. Neuropeptide FF is present in mammalian central nervous system and periphery, with NPFF-immunoreactivity increases in rat cerebrospinal fluid during opiate tolerance, and its NPFF gene and NPFF-R2 gene are up-regulated in rat spinal cord and dorsal root ganglia during peripheral inflammation. Neuropeptide FF can be used for the research of opioid tolerance, morphine-induced analgesia, abstinence syndrome, pain, hypertension, nociception, inflammatory pain, and neuropathic pain .

HY-P1290

PKA Inhibitor Fragment (6-22) amide 5 Publications Verification PKI-(6-22)-amide	PKA	Neurological Disease
PKA Inhibitor Fragment (6-22) amide is a highly potent and specific competitive inhibitor of PKA, with K_i values of 1.7 nM and 1.6 nM against human and bovine PKA catalytic subunits, respectively. The IC₅₀ of PKA Inhibitor Fragment (6-22) amide targeting bovine PKA is 8.6 nM. PKA Inhibitor Fragment (6-22) amide effectively abolishes PKA activity in mouse brain and spinal cord, and exerts in vivo efficacy via intracerebroventricular administration. PKA Inhibitor Fragment (6-22) amide significantly reverses low-dose morphine analgesic tolerance in mice and blocks photoaffinity labeling of cAMP-dependent protein kinase. PKA Inhibitor Fragment (6-22) amide can be applied to research in fields related to the mechanism of morphine analgesic tolerance and skin wound healing .

HY-P1701

Morphiceptin	Opioid Receptor	Cardiovascular Disease Neurological Disease
Morphiceptin is a potent and specific agonist for morphine (μ) receptors. Morphiceptin, as a synthetic peptide, is the amide of a fragment of the milk protein β-casein. Morphiceptin has morphinelike activities and is highly specific for morphine (μ) receptors but not for Enkephalin receptors .

HY-147428

Zolunicant MM-110; (±)-18-Methoxycoronaridine	nAChR Parasite	Infection Neurological Disease
Zolunicant (MM-110) is a potent inhibitor against nicotinic α3β4 receptors with an IC₅₀ of 0.90 μM to combat addiction. Zolunicant can decrease the self-administration of several addictive agents including morphine, methamphetamine, nicotine, and ethanol in rat model. Zolunicant can be studied as a potential research for multiple forms of agent abuse . Zolunicant also reveals a potent leishmanicide effect against Leishmania amazonensis .

HY-106840

L-365260 2 Publications Verification	Cholecystokinin Receptor	Neurological Disease Metabolic Disease
L-365260 is an orally active and selective antagonist of non-peptide gastrin and brain cholecystokinin receptor (CCK-B), with K_is of 1.9 nM and 2.0 nM, respectively. L-365260 interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain CCK receptors. L-365260 can enhance Morphine analgesia and prevents Morphine tolerance .

HY-P1290A

PKA Inhibitor Fragment (6-22) amide TFA 5 Publications Verification PKI-(6-22)-amide TFA	PKA	Neurological Disease
PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependent protein kinase A (PKA), with a K_i of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA can significantly reverse antinociceptive tolerance in mice .

HY-P2259

TAT-GluA2 3Y 2 Publications Verification	iGluR HIV Integrase Adenosine Receptor	Cardiovascular Disease Neurological Disease
TAT-GluA2 3Y is a blood-brain barrier-permeable AMPA receptor inhibitory peptide that crosses cell membranes via the HIV-1 TAT protein domain. TAT-GluA2 3Y blocks the endocytosis of AMPA receptors, including the internalization of GluA1/GluA2 subunits, by disrupting interactions with the AP2, Brag2 and Syt3-GluA2 complexes, while also inhibiting long-term depression. TAT-GluA2 3Y blocks hypoxia-mediated AMPAR internalization, alleviates A1R-induced persistent synaptic inhibition, and reduces cerebral ischemic volume, neurological deficits and spatial memory deficits. TAT-GluA2 3Y blocks the effect of NLRP3 deficiency on fear generalization, inhibits amphetamine-induced behavioral/neurochemical sensitization, weakens the unconditioned stimulus-conditioned stimulus association of morphine, and promotes the extinction of morphine CPP. TAT-GluA2 3Y can be used in studies related to fear generalization, ischemic stroke, hypoxia, drug addiction and opioid addiction .

HY-N1356A

(R)-Reticuline	Cytochrome P450	Inflammation/Immunology
(R)-Reticuline is a key intermediate and precursor in the biosynthetic pathway of morphinan alkaloids. (R)-Reticuline plays a central role in the metabolism of opium poppy (Papaver somniferum). (R)-Reticuline can either undergo O-methylation catalyzed by PSOMT1, or be converted to (+)-Salutaridine via regioselective and stereoselective oxidative coupling under the action of salutaridine synthase (CYP719B1). (R)-Reticuline serves as a direct precursor for the synthesis of important alkaloids such as morphine, codeine and thebaine .

HY-P1284

ZIP 2 Publications Verification	PKC	Neurological Disease Cancer
ZIP is a selective peptide inhibitor of PKMζ. ZIP injections can block the impairment in morphine conditioned place preference induced .

HY-104006

CYM51010	Opioid Receptor	Neurological Disease
CYM51010 is a biased ligand of μ-opioid receptor – δ-opioid receptor heterodimers with an EC₅₀ of 403 nM. CYM51010 exhibits anti-nociceptive activity similar to morphine but with a decreased levels of tolerance development and withdrawal symptoms .

HY-W013113

BTMPS	Environmental Pollutants nAChR	Neurological Disease
BTMPS is a nicotine receptor (nAChR) antagonist that can lessen the negative effects of morphine on rats .

HY-108229

6β-Naltrexol 6β-Hydroxynaltrexone	Drug Metabolite Opioid Receptor	Neurological Disease
6β-Naltrexol (6β-Hydroxynaltrexone), the primary metabolite of Naltrexone, is a peripherally selective opioid antagonist. 6β-Naltrexol selectively inhibits gastrointestinal opioid effects in human subjects and inhibits Morphine-induced slowing of gastrointestinal transit .

HY-W152604

Cyclo(glycyl-L-leucyl) Cyclo(leu-gly)	Dopamine Receptor	Neurological Disease
Cyclo(glycyl-L-leucyl) (Cyclo(leu-gly)), a neuropeptide, down-regulates dopamine (DA) receptors and attenuates dopaminergic supersensitivity. Cyclo(glycyl-L-leucyl) inhibits the development of Morphine induced pain relief as well as dopamine receptor supersensitivity in rats. Cyclo(glycyl-L-leucyl) has the potential for the prevention of tardive and/or L-DOPA (HY-N0304)-induced dyskinesias .

HY-101352

LY 225910	Cholecystokinin Receptor	Neurological Disease
LY 225910 is a selective antagonist for cholecystokinin receptor (CCK2 receptor), which affects the excitatory response to morphine, and leads to morphine sensitization .

HY-136208

TAN-452	Opioid Receptor	Neurological Disease
TAN-452 is an orally active, selective peripherally acting δ-opioid receptor (DOR) antagonist with a K_i of 0.47 nM and a K_b of 0.21 nM. TAN-452 is an antagonist for μ-opioid receptor (MOR; K_i=36.56 nM and K_b=9.43 nM) and κ-opioid receptor (KOR; K_i=5.31 nM and K_b=7.18 nM). TAN-452, a derivative of Naltrindole, demonstrates low brain penetrability and attenuates morphine-induced side effects without affecting pain control .

HY-P3870

DALDA	Opioid Receptor	Neurological Disease
DALDA is a potent and highly selective μ-opioid receptor agonist with a K_i of 1.69 nM. DALDA shows antinociceptive and respiratory effects .

HY-138885

Tryptamine guanosine carbamate TpGc	Tyrosinase DNA/RNA Synthesis	Neurological Disease
Tryptamine guanosine carbamate (TpGc) is a selective HINT1 (histidine triad nucleotide-binding protein 1) inhibitor (K_i=34 μM, K_d=3.65 μM). Tryptamine guanosine carbamate significantly enhances morphine antinociception while preventing the development of tolerance .

HY-108229S

6β-Naltrexol-d3 6β-Hydroxynaltrexone-d₃	Isotope-Labeled Compounds Opioid Receptor Drug Metabolite	Neurological Disease
6β-Naltrexol-d₃ (6β-Hydroxynaltrexone-d₃) is deuterium labeled 6β-Naltrexol. 6β-Naltrexol (6β-Hydroxynaltrexone), the primary metabolite of Naltrexone, is a peripherally selective opioid antagonist. 6β-Naltrexol selectively inhibits gastrointestinal opioid effects in human subjects and inhibits Morphine-induced slowing of gastrointestinal transit .

HY-N1989

Bacoside A	Na+/K+ ATPase CaMK Apoptosis Cholinesterase (ChE) NO Synthase NF-κB	Neurological Disease Cancer
Bacoside A is an orally active, blood-brain barrier-permeable triterpenoid saponin that modulates the activities of ATPases, AChE, CaMK2A and iNOS. Derived from Bacopa monniera. Bacoside A exerts significant antioxidant, anti-inflammatory and anti-apoptotic effects by maintaining ion balance, scavenging reactive oxygen species, stabilizing cell membranes, and regulating the expression of NF-κB and apoptosis-related proteins. Bacoside A counteracts morphine-induced reductions in Na ⁺/K ⁺-ATPase, Ca ²⁺-ATPase and Mg ²⁺-ATPase activities, increases mitochondrial membrane potential, and decreases intracellular reactive oxygen species levels. Bacoside A specifically binds to calcium/calmodulin-dependent protein kinase IIA to trigger endoplasmic reticulum calcium release. Bacoside A exhibits non-apoptotic cytotoxicity against glioblastoma cells while protecting normal nerve cells from stress-induced damage. Bacoside A is applicable to the research of Parkinson's disease and glioblastoma multiforme .

HY-116181

YQA14	Dopamine Receptor	Neurological Disease
YQA14 is a high affinity dopamine D3 receptor antagonist. YQA14 is anti-opioid addiction agent. YQA14 inhibits Morphine/Cocaine-induced conditioned place preference (CPP) in animals .

HY-123468

HA-1004	Cyclic GMP-AMP Synthase PKA ERK Tyrosine Hydroxylase Calcium Channel	Cardiovascular Disease Metabolic Disease
HA-1004 is a selective inhibitor of PKA, which can inhibit lipolysis and induce vascular relaxation. HA-1004 is also a dual inhibitor of cyclic GMP-dependent protein kinase and cyclic AMP-dependent protein, and is involved in smooth muscle, second messenger, cyclic AMP and cyclic GMP regulation mechanisms. HA-1004 is an antagonist for calcium, that can be used as a vasodilator to inhibit the contraction of rabbit aortic strips, or to antagonize ERK and tyrosine hydroxylase (TH) phosphorylation in morphine abstinence rat models .

HY-P3870A

DALDA acetate	Opioid Receptor	Neurological Disease
DALDA acetate is a potent and highly selective μ-opioid receptor agonist with a K_i of 1.69 nM. DALDA acetate shows antinociceptive and respiratory effects .

HY-110099

(±)-NBI-74330	CXCR	Inflammation/Immunology
(±)-NBI-74330 is a potent and selective CXCR3 antagonist. (±)-NBI-74330 not only reduces tactile and thermal hypersensitivity but also enhances the analgesic properties of morphine. (±)-NBI-74330 can reduce microglial cell activation, increase astroglial cell activation, and downregulate the expression of some CXCR3 ligands in a rat neuropathic pain model .

HY-155850

CIAC001	Pyruvate Kinase	Neurological Disease
CIAC001 is a Pyruvate Kinase PKM2 inhibitor with anti-neuroinflammatory activity. CIAC001 inhibits LPS-induced proinflammatory nitric oxide (NO) production and protects immunologically active BV-2 cells (IC₅₀=2.5 μM). CIAC001 also has anti-neuroinflammation in mouse models and inhibits chronic morphine-induced addiction .

HY-B0424S

Nitrendipine-d5 AY-E-5009-d₅	Isotope-Labeled Compounds Calcium Channel Apoptosis	Cardiovascular Disease Neurological Disease Cancer
Nitrendipine-d₅ is the deuterium labeled Nitrendipine (HY-B0424). Nitrendipine (BAY-E-5009) is an orally active analog of Nifedipine (HY-B0284) and dihydropyridine calcium channel blocker. Nitrendipine induces Apoptosis. Nitrendipine has antihypertensive effects. Nitrendipine blocks alcohol and Morphine withdrawal symptoms. Nitrendipine reduces right ventricular hypertrophy and pulmonary vascular changes induced by intermittent hypoxia. Nitrendipine has anticancer effects on neuroblastoma .

HY-P1329

CTOP	Opioid Receptor	Neurological Disease
CTOP is a potent and highly selective μ-opioid receptor antagonist. CTOP antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP enhances extracellular dopamine levels in the nucleus accumbens. CTOP dose-dependently enhances locomotor activity .

HY-P1216

HS014	Melanocortin Receptor	Neurological Disease
HS014 is a potent and selective melanocortin-4 (MC4) receptor antagonist, with K_is of 3.16, 108, 54.4 and 694 nM for human MC4, MC1, MC3 and MC5 receptors, respectively. HS014 modulates the behavioral effects of morphine in mice. HS014 increases food intake in free-feeding rats .

HY-178235

MDAN-21	Opioid Receptor	Neurological Disease
MDAN-21 is a bivalent opioid ligand that contains both μ-opioid receptor agonists and δ-opioid receptor antagonists. MDAN-21 has a strong analgesic effect and does not produce tolerance in mouse studies. MDAN-21 can effectively inhibit the withdrawal of morphine dependent monkeys and alleviate abnormal pain in the study of rhesus monkeys. MDAN-21 can be used for the study of allodynia .

HY-B0424R

Nitrendipine (Standard) BAY-E-5009 (Standard)	Reference Standards Calcium Channel Apoptosis	Cardiovascular Disease Neurological Disease Cancer
Nitrendipine (Standard) is the analytical standard of Nitrendipine (HY-B0424). This product is intended for research and analytical applications. Nitrendipine (BAY-E-5009) is an orally active analog of Nifedipine (HY-B0284) and dihydropyridine calcium channel blocker. Nitrendipine induces Apoptosis. Nitrendipine has antihypertensive effects. Nitrendipine blocks alcohol and Morphine withdrawal symptoms. Nitrendipine reduces right ventricular hypertrophy and pulmonary vascular changes induced by intermittent hypoxia. Nitrendipine has anticancer effects on neuroblastoma .

HY-112348

HA-1004 hydrochloride	Cyclic GMP-AMP Synthase PKA ERK Calcium Channel	Cardiovascular Disease Metabolic Disease
HA-1004 hydrochloride is a selective inhibitor of PKA, which can inhibit lipolysis and induce vascular relaxation. HA-1004 hydrochloride is also a dual inhibitor of cyclic GMP-dependent protein kinase and cyclic AMP-dependent protein (Cyclic GMP-AMP Synthase), and is involved in smooth muscle, second messenger, cyclic AMP and cyclic GMP regulation mechanisms. HA-1004 hydrochloride an antagonist for calcium, that can be used as a vasodilator to inhibit the contraction of rabbit aortic strips, or to antagonize ERK and tyrosine hydroxylase (TH) phosphorylation in morphine abstinence rat models .

HY-169469

N-Phenethylnoroxymorphone	Opioid Receptor	Neurological Disease
N-Phenethylnoroxymorphone is an opioid compound. N-Phenethylnoroxymorphone enhances morphine-induced analgesia in rats. N-Phenethylnoroxymorphone can be used for research on neurological diseases .

HY-144606

Mu opioid receptor antagonist 1	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 1 (compound 19) is a selective and orally active μ opioid receptor (MOR) ligand with an K_i value of 0.58 nM and an EC₅₀ of 1.15 nM. Orally administrating with Mu opioid receptor antagonist 1 increases intestinal motility during morphine-induced constipation. Mu opioid receptor antagonist 1 can be used for researching opioid-induced constipation (OIC) .

HY-144609

Mu opioid receptor antagonist 4	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 4 (compound 31) is a potent and selective μ opioid receptor (MOR) antagonist with a K_i of 0.38 nM and an EC₅₀ of 1.07 nM. Mu opioid receptor antagonist 4 has remarkable CNS antagonism against morphine, and precipitated fewer withdrawal symptoms than Naloxone. Mu opioid receptor antagonist 4 Mu opioid receptor antagonist 4 can be used for researching opioid use disorders (OUD) .

HY-144607

Mu opioid receptor antagonist 2	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 2 (compound 25) is a potent, selective and blood-brain barrier (BBB) penetrant μ opioid receptor (MOR) antagonist with a K_i of 0.37 nM and an EC₅₀ of 0.44 nM. Mu opioid receptor antagonist 2 has remarkable CNS antagonism against morphine, and precipitated fewer withdrawal symptoms than Naloxone. Mu opioid receptor antagonist 2 can be used for researching opioid use disorders (OUD) .

HY-173016

HINT1-IN-1	Opioid Receptor	Neurological Disease
HINT1-IN-1 (Compound 8) is the inhibitor for histidine triad nucleotide-binding protein 1 (HINT1) with a K_i of 1.14 μM. HINT1-IN-1 affects the cross-regulation between μ-opioid receptor (MOR) and NMDA receptor (NMDAR). HINT1-IN-1 enhances the analgesic effect of morphine without causing opioid tolerance and has independent analgesic effects in mouse model .

HY-171758

BU72	Opioid Receptor	Neurological Disease
BU72 is a highly potent and long-acting agonist of μ and κ opioid receptors, and also has a partial agonist effect on δ opioid receptors (EC₅₀ values are 0.054, 0.033, and 0.58 nM, respectively). BU72 has a strong and long-lasting analgesic effect, which is mainly mediated by μ opioid receptors. BU72 has a long-lasting activity and can partially reverse the analgesic effect of morphine. BU72 can be used in the study of opioid dependence .

HY-16900R

Rolipram (Standard) (R,S)-Rolipram (Standard); (±)-Rolipram (Standard); ZK 62711 (Standard)	Reference Standards Bacterial HIV Phosphodiesterase (PDE) Epigenetic Reader Domain Amyloid-β	Neurological Disease Cancer
Rolipram (Standard) is the analytical standard of Rolipram (HY-16900). This product is intended for research and analytical applications. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

HY-149274

Sigma-1 receptor antagonist 4	Sigma Receptor	Neurological Disease
Sigma-1 receptor antagonist 4 (Compound 32) is a potent σ1R antagonist that significantly enhances the analgesic effect of morphine and rescues morphine-induced analgesic tolerance, with potential to prevent morphine tolerance .

HY-119174

MK771	Thyroid Hormone Receptor	Neurological Disease
MK771 is a thyrotrophin-releasing hormone analog. MK771 induces blinking and forepaw licking. MK771 has the potential for the research of morphine abstinence syndrome .

HY-144608

Mu opioid receptor antagonist 3	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 3 (compound 26) is a potent and selective μ opioid receptor (MOR) antagonist with a K_i of 0.24 nM and an EC₅₀ of 0.54 nM. Mu opioid receptor antagonist 3 has remarkable CNS antagonism against morphine, and precipitated fewer withdrawal symptoms than Naloxone. Mu opioid receptor antagonist 3 can be used for researching opioid use disorders (OUD) .

HY-123468A

HA-1004 dihydrochloride	Cyclic GMP-AMP Synthase PKA ERK Calcium Channel	Cardiovascular Disease Metabolic Disease
HA-1004 dihydrochloride is a selective inhibitor of PKA, which can inhibit lipolysis and induce vascular relaxation. HA-1004 dihydrochloride is also a dual inhibitor of cyclic GMP-dependent protein kinase and cyclic AMP-dependent protein, and is involved in smooth muscle, second messenger, cyclic AMP and cyclic GMP regulation mechanisms. HA-1004 dihydrochloride is an antagonist for calcium, that can be used as a vasodilator to inhibit the contraction of rabbit aortic strips, or to antagonize ERK and tyrosine hydroxylase (TH) phosphorylation in morphine abstinence rat models .

HY-P5061

Dynorphin A (1-13) amide	Opioid Receptor	Neurological Disease
Dynorphin A (1-13) amide is an endogenous opioid peptide that antagonizes morphine-induced analgesia .

Cat. No.	Product Name

HY-L071

Alkaloids Library

599 compounds

Alkaloids are a large and complex group of cyclic compounds that contain N. About 2,000 different alkaloids have been isolated. Important alkaloids include morphine, strychnine, atropine, colchicine, ephedrine, quinine, and nicotine. Alkaloids are useful as diet ingredients, supplements, and pharmaceuticals, in medicine and in other applications in human life. They showed anti-inflammatory, anticancer, analgesics, local anesthetic and pain relief, neuropharmacologic, antimicrobial, antifungal, and many other activities. Alkaloids are also important compounds in organic synthesis for searching new semisynthetic and synthetic compounds with possibly better biological activity than parent compounds.

MCE designs a unique collection of 599 alkaloids that all come from natural products. MCE Alkaloids Library is a useful tool for drug discovery that can be used for high throughput screening (HTS) and high content screening (HCS).

Cat. No.	Product Name	Target	Research Area

HY-P0288

[Leu5]-Enkephalin 2 Publications Verification Leu-enkephalin; Leucine enkephalin; Leucyl-enkephalin	Opioid Receptor Endogenous Metabolite	Neurological Disease
[Leu5]-Enkephalin is a pentapeptide with morphine like properties. [Leu5]-Enkephalin is a five amino acid endogenous peptide that acts as an agonist at opioid receptors.

HY-P1291

PKI 14-22 amide,myristoylated 3 Publications Verification	PKA Epigenetic Reader Domain Flavivirus	Infection Neurological Disease
PKI 14-22 amide, myristoylated is a selective, cAMP-dependent, competitive PKA inhibitor with K_i=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated can prevent the development of morphine analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated can be used in research fields such as opioid tolerance mechanisms and antiviral drugs .

HY-P1248

Neuropeptide FF NPFF	Neuropeptide FF Receptor	Cardiovascular Disease Neurological Disease
Neuropeptide FF (NPFF), an octapeptide belonging to the RF-amide family of peptides, is a NPFF1 and NPFF2 receptors agonist with K_i values of 2.82 nM and 0.21 nM, respectively. Neuropeptide FF induces abstinence syndrome, exerts antiopioid and analgesic effects, releases via calcium-dependent mechanisms from rat spinal cord, regulates memory, autonomic function, and neuroendocrine function, modulates pain and opioid antinociception, reduces food intake, stimulates water intake, alters cardiovascular parameters, and shows differential activity in hypothalamic paraventricular nucleus neurons. Neuropeptide FF is present in mammalian central nervous system and periphery, with NPFF-immunoreactivity increases in rat cerebrospinal fluid during opiate tolerance, and its NPFF gene and NPFF-R2 gene are up-regulated in rat spinal cord and dorsal root ganglia during peripheral inflammation. Neuropeptide FF can be used for the research of opioid tolerance, morphine-induced analgesia, abstinence syndrome, pain, hypertension, nociception, inflammatory pain, and neuropathic pain .

HY-P1290

PKA Inhibitor Fragment (6-22) amide 5 Publications Verification PKI-(6-22)-amide	PKA	Neurological Disease
PKA Inhibitor Fragment (6-22) amide is a highly potent and specific competitive inhibitor of PKA, with K_i values of 1.7 nM and 1.6 nM against human and bovine PKA catalytic subunits, respectively. The IC₅₀ of PKA Inhibitor Fragment (6-22) amide targeting bovine PKA is 8.6 nM. PKA Inhibitor Fragment (6-22) amide effectively abolishes PKA activity in mouse brain and spinal cord, and exerts in vivo efficacy via intracerebroventricular administration. PKA Inhibitor Fragment (6-22) amide significantly reverses low-dose morphine analgesic tolerance in mice and blocks photoaffinity labeling of cAMP-dependent protein kinase. PKA Inhibitor Fragment (6-22) amide can be applied to research in fields related to the mechanism of morphine analgesic tolerance and skin wound healing .

HY-P1701

Morphiceptin	Opioid Receptor	Cardiovascular Disease Neurological Disease
Morphiceptin is a potent and specific agonist for morphine (μ) receptors. Morphiceptin, as a synthetic peptide, is the amide of a fragment of the milk protein β-casein. Morphiceptin has morphinelike activities and is highly specific for morphine (μ) receptors but not for Enkephalin receptors .

HY-P1290A

PKA Inhibitor Fragment (6-22) amide TFA 5 Publications Verification PKI-(6-22)-amide TFA	PKA	Neurological Disease
PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependent protein kinase A (PKA), with a K_i of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA can significantly reverse antinociceptive tolerance in mice .

HY-P2259

TAT-GluA2 3Y 2 Publications Verification	iGluR HIV Integrase Adenosine Receptor	Cardiovascular Disease Neurological Disease
TAT-GluA2 3Y is a blood-brain barrier-permeable AMPA receptor inhibitory peptide that crosses cell membranes via the HIV-1 TAT protein domain. TAT-GluA2 3Y blocks the endocytosis of AMPA receptors, including the internalization of GluA1/GluA2 subunits, by disrupting interactions with the AP2, Brag2 and Syt3-GluA2 complexes, while also inhibiting long-term depression. TAT-GluA2 3Y blocks hypoxia-mediated AMPAR internalization, alleviates A1R-induced persistent synaptic inhibition, and reduces cerebral ischemic volume, neurological deficits and spatial memory deficits. TAT-GluA2 3Y blocks the effect of NLRP3 deficiency on fear generalization, inhibits amphetamine-induced behavioral/neurochemical sensitization, weakens the unconditioned stimulus-conditioned stimulus association of morphine, and promotes the extinction of morphine CPP. TAT-GluA2 3Y can be used in studies related to fear generalization, ischemic stroke, hypoxia, drug addiction and opioid addiction .

HY-P1284

ZIP 2 Publications Verification	PKC	Neurological Disease Cancer
ZIP is a selective peptide inhibitor of PKMζ. ZIP injections can block the impairment in morphine conditioned place preference induced .

HY-W152604

Cyclo(glycyl-L-leucyl) Cyclo(leu-gly)	Dopamine Receptor	Neurological Disease
Cyclo(glycyl-L-leucyl) (Cyclo(leu-gly)), a neuropeptide, down-regulates dopamine (DA) receptors and attenuates dopaminergic supersensitivity. Cyclo(glycyl-L-leucyl) inhibits the development of Morphine induced pain relief as well as dopamine receptor supersensitivity in rats. Cyclo(glycyl-L-leucyl) has the potential for the prevention of tardive and/or L-DOPA (HY-N0304)-induced dyskinesias .

HY-P3870

DALDA	Opioid Receptor	Neurological Disease
DALDA is a potent and highly selective μ-opioid receptor agonist with a K_i of 1.69 nM. DALDA shows antinociceptive and respiratory effects .

HY-P3870A

DALDA acetate	Opioid Receptor	Neurological Disease
DALDA acetate is a potent and highly selective μ-opioid receptor agonist with a K_i of 1.69 nM. DALDA acetate shows antinociceptive and respiratory effects .

HY-P1329

CTOP	Opioid Receptor	Neurological Disease
CTOP is a potent and highly selective μ-opioid receptor antagonist. CTOP antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP enhances extracellular dopamine levels in the nucleus accumbens. CTOP dose-dependently enhances locomotor activity .

HY-P1216

HS014	Melanocortin Receptor	Neurological Disease
HS014 is a potent and selective melanocortin-4 (MC4) receptor antagonist, with K_is of 3.16, 108, 54.4 and 694 nM for human MC4, MC1, MC3 and MC5 receptors, respectively. HS014 modulates the behavioral effects of morphine in mice. HS014 increases food intake in free-feeding rats .

HY-P3628

Dynorphin (2-17) (porcine)	Peptides	Neurological Disease
Dynorphin (2-17) (porcine) is a peptide derived from Prodynorphin, can improve somatic signs of Morphine-dependent withdrawal .

HY-P5061

Dynorphin A (1-13) amide	Opioid Receptor	Neurological Disease
Dynorphin A (1-13) amide is an endogenous opioid peptide that antagonizes morphine-induced analgesia .

HY-P1284A

ZIP TFA	PKC	Neurological Disease Cancer
ZIP TFA is a selective peptide inhibitor of PKMζ. ZIP TFA injections can block the impairment in morphine conditioned place preference induced .

HY-P10555

(D-Arg2, Sar 4)-Dermorphin (1-4)	Opioid Receptor	Neurological Disease
(D-Arg2, Sar 4)-Dermorphin (1-4) is a tetrapeptide derivative of the peptide Dermorphin (HY-P0244) found in amphibian skin. (D-Arg2, Sar 4)-Dermorphin (1-4) has significant analgesic effects by binding to the μ-opioid receptor (MOR) in the body. (D-Arg2, Sar 4)-Dermorphin (1-4) can be used in the development of analgesic drugs .

HY-P0288A

[Leu5]-Enkephalin TFA	Opioid Receptor Endogenous Metabolite	Neurological Disease
[Leu5]-Enkephalin TFA is a pentapeptide with morphine like properties. [Leu5]-Enkephalin TFA is a five amino acid endogenous peptide that acts as an agonist at opioid receptors.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P0288

[Leu5]-Enkephalin 2 Publications Verification Leu-enkephalin; Leucine enkephalin; Leucyl-enkephalin	Natural Products Monophenols Phenols Endogenous metabolite Source Classification	Opioid Receptor Endogenous Metabolite
[Leu5]-Enkephalin is a pentapeptide with morphine like properties. [Leu5]-Enkephalin is a five amino acid endogenous peptide that acts as an agonist at opioid receptors.

HY-N0541

Pseudoginsenoside F11 2 Publications Verification Ginsenoside A1	Panax ginseng C. A. Meyer Triterpenes Classification of Application Fields Terpenoids Other Diseases Plants Endogenous metabolite Disease Research Fields Araliaceae Source Classification	Endogenous Metabolite
Pseudoginsenoside F11 (Ginsenoside A1), a component of Panax quinquefolium (American ginseng), has been demonstrated to antagonize the learning and memory deficits induced by scopolamine, morphine and methamphetamine in mice.

HY-N1356A

(R)-Reticuline	Structural Classification Alkaloids Plants Lauraceae Isoquinoline Alkaloids Lindera aggregata (Sims) Kosterm. Source Classification	Cytochrome P450
(R)-Reticuline is a key intermediate and precursor in the biosynthetic pathway of morphinan alkaloids. (R)-Reticuline plays a central role in the metabolism of opium poppy (Papaver somniferum). (R)-Reticuline can either undergo O-methylation catalyzed by PSOMT1, or be converted to (+)-Salutaridine via regioselective and stereoselective oxidative coupling under the action of salutaridine synthase (CYP719B1). (R)-Reticuline serves as a direct precursor for the synthesis of important alkaloids such as morphine, codeine and thebaine .

HY-N1989

Bacoside A	Triterpenes Structural Classification Classification of Application Fields Terpenoids Scrophulariaceae Metabolic Disease Plants Disease Research Fields Bacopa monnieri (Linn.) Wettst. Source Classification	Na+/K+ ATPase CaMK Apoptosis Cholinesterase (ChE) NO Synthase NF-κB
Bacoside A is an orally active, blood-brain barrier-permeable triterpenoid saponin that modulates the activities of ATPases, AChE, CaMK2A and iNOS. Derived from Bacopa monniera. Bacoside A exerts significant antioxidant, anti-inflammatory and anti-apoptotic effects by maintaining ion balance, scavenging reactive oxygen species, stabilizing cell membranes, and regulating the expression of NF-κB and apoptosis-related proteins. Bacoside A counteracts morphine-induced reductions in Na ⁺/K ⁺-ATPase, Ca ²⁺-ATPase and Mg ²⁺-ATPase activities, increases mitochondrial membrane potential, and decreases intracellular reactive oxygen species levels. Bacoside A specifically binds to calcium/calmodulin-dependent protein kinase IIA to trigger endoplasmic reticulum calcium release. Bacoside A exhibits non-apoptotic cytotoxicity against glioblastoma cells while protecting normal nerve cells from stress-induced damage. Bacoside A is applicable to the research of Parkinson's disease and glioblastoma multiforme .

Cat. No.	Product Name	Chemical Structure

HY-108229S

6β-Naltrexol-d3
6β-Naltrexol-d₃ (6β-Hydroxynaltrexone-d₃) is deuterium labeled 6β-Naltrexol. 6β-Naltrexol (6β-Hydroxynaltrexone), the primary metabolite of Naltrexone, is a peripherally selective opioid antagonist. 6β-Naltrexol selectively inhibits gastrointestinal opioid effects in human subjects and inhibits Morphine-induced slowing of gastrointestinal transit .

HY-B0424S

Nitrendipine-d5

Nitrendipine-d₅ is the deuterium labeled Nitrendipine (HY-B0424). Nitrendipine (BAY-E-5009) is an orally active analog of Nifedipine (HY-B0284) and dihydropyridine calcium channel blocker. Nitrendipine induces Apoptosis. Nitrendipine has antihypertensive effects. Nitrendipine blocks alcohol and Morphine withdrawal symptoms. Nitrendipine reduces right ventricular hypertrophy and pulmonary vascular changes induced by intermittent hypoxia. Nitrendipine has anticancer effects on neuroblastoma .

Cat. No.	Product Name		Classification

HY-138885

Tryptamine guanosine carbamate TpGc		Nucleoside Analogs Guanosine
Tryptamine guanosine carbamate (TpGc) is a selective HINT1 (histidine triad nucleotide-binding protein 1) inhibitor (K_i=34 μM, K_d=3.65 μM). Tryptamine guanosine carbamate significantly enhances morphine antinociception while preventing the development of tolerance .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Morphine

Inhibitors & Agonists

Screening Libraries

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products